The Dermatology Digest

MARCH 17, 2025

has enrolled of the first patient in a Phase 2 trial of EVO301, an injectable interleukin (IL)-18 neutralizer, in moderate-to-severe atopic dermatitis (AD). EASI, the Eczema Area and Severity Index score, isa tool used to measure the extent and severity of atopic dermatitis. Evommune, Inc.

Dermatitis 36

Dermatitis Eczema Injections Tools 36

Dermatology Times

MARCH 14, 2025

Panelists discuss how JAK inhibitors demonstrate significant efficacy in treating atopic dermatitis while examining their safety profiles and optimal positioning within the therapeutic landscape.

Safety 36

Safety Dermatitis Therapy 36

Dermatology Times

MARCH 10, 2025

Panelists discuss the newer systemic treatment options for pediatric atopic dermatitis (AD), including tralokinumab, JAK inhibitors, and nemolizumab, focusing on their mechanisms of action, efficacy, and safety profiles in treating moderate to severe cases of the condition in children.

Dermatitis 53

Dermatitis Therapy Safety Treatments 53

Dermatology Times

MARCH 21, 2025

Panelists discuss how health care providers can effectively communicate the benefits and risks of JAK inhibitors to patients with atopic dermatitis while addressing safety concerns and establishing realistic treatment expectations.

Safety 36

Safety Dermatitis Treatments 36

The Dermatology Digest

MARCH 10, 2025

Amgen and Kyowa Kirins rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, met its co-primary endpoints and all key secondary endpoints in moderate-to-severe atopic dermatitis (AD) study, the Companies report. In the lower dose group, 36.3% of patients achieved EASI-75, a 23.4% difference vs. placebo.

Dermatitis 36

Dermatitis Safety Office Eczema 36

Dermatology Times

JUNE 10, 2024

Amy Paller, MD, reviews the various types of therapeutics available and coming soon for pediatric atopic dermatitis and how she decides what treatment approach is best for each patient.

Safety 73

Safety Treatments Dermatitis 73

Dermatology Times

NOVEMBER 19, 2024

Patients with moderate to severe atopic dermatitis saw the most improvement after taking 600 mg of tozorakimab.

Safety 74

Safety Dermatitis 74

Dermatology Times

JANUARY 2, 2025

The panelist discusses how safety data from clinical trials and real-world evidence should guide physicians in prescribing ruxolitinib cream, including patient monitoring protocols and managing potential adverse effects in atopic dermatitis treatment.

Safety 36

Safety Dermatitis Management Clinic 36

The Dermatology Digest

JANUARY 10, 2025

is initiating a Phase 2b dose-ranging trial for its CGB-500 (1% tofacitinib), a topical Janus kinase (JAK) inhibitor ointment for moderate to severe atopic dermatitis (AD) and low body surface area (BSA) involvement. CAGE Bio, Inc. CGB-500 was developed using CAGE Bio’s proprietary ionic liquid technology.

Dermatitis 36

Dermatitis Safety Technology Dermatology 36

Dermatology Times

DECEMBER 11, 2023

Christopher Bunick, MD, PhD, presented the research during a late-breaking research session during the 2023 Revolutionizing Atopic Dermatitis Virtual Conference.

Safety 74

Safety Management Dermatitis 74

The Dermatology Digest

JANUARY 22, 2025

The SNDS is supported by data from Arcutis pivotal ARRECTOR (A Randomized tRial Employing topiCal roflumilasT foam to treat scalp psORiasis) Phase 3 trial, a Phase 2b study, and long-term efficacy and safety data generated from thecream development program in plaque psoriasis. of individuals treated with vehicle. Roumilast cream 0.3%

Dermatitis 36

Dermatitis Safety Treatments Clinic 36

Dermatology Times

DECEMBER 18, 2023

Pusan National University published the review in light of the growing body of JAK inhibitors in the AD space.

Safety 74

Safety Dermatitis 74

Dermatology Times

MAY 13, 2024

They are confident prescribing roflumilast to patients with diverse skin and hair characteristics, including those with a history of hair treatments.

Safety 74

Safety Dermatitis Treatments 74

The Dermatology Digest

DECEMBER 13, 2024

Food and Drug Administration (FDA) has approved nemolizumab (Nemluvio, Galderma) for the treatment of patients aged 12 and older with moderate to severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies.

Dermatitis 69

Dermatitis Safety Eczema Dermatology 69

Dermatology Times

OCTOBER 24, 2024

Findings from 2 phase 3 trials indicate that ZORYVE cream significantly improves both clinical outcomes and quality of life in patients with mild to moderate atopic dermatitis.

Safety 53

Safety Dermatitis Clinic 53

Dermatology Times

JANUARY 11, 2024

The additional efficacy data highlights tapinarof cream 1% and its impact on EASI, PP-NRS, ViGA-AD, and more.

Safety 73

Safety Dermatitis 73

Dermatology Times

MARCH 12, 2025

Ruxolitinib cream showlasting safety and efficacy in children with moderate to severe atopic dermatitis.

Dermatitis 59

Dermatitis Safety 59

Dermatology Times

MARCH 28, 2025

Lisa Swanson, MD, FAAD, discusses how pediatric atopic dermatitis (AD) treatment challenges include limited approved options, safety concerns, and adherence issues. Effective management requires balancing new therapies like Janus kinase (JAK) inhibitors with safety while supporting caregivers through education.

Dermatitis 36

Dermatitis Safety Education Therapy 36

Dermatology Times

MARCH 14, 2025

Panelists discuss how varying degrees of JAK selectivity in targeted therapies affect treatment outcomes, safety profiles, and therapeutic decision-making in atopic dermatitis management.

Dermatitis 36

Dermatitis Treatments Safety Therapy 36

The Dermatology Digest

SEPTEMBER 26, 2024

Food and Drug Administration approved for prurigo nodularis (PN), nemolizumab (Nemluvio, Galderma) improved signs and symptoms of atopic dermatitis for more than one year, according to the ARCADIA open-label extension study. The safety profile was consistent with that previously reported, the study showed. Safety is not an issue.

Dermatitis 74

Dermatitis Safety Management Eczema 74

The Dermatology Digest

JANUARY 13, 2025

Nektar Therapeutics has completed target enrollment in its REZOLVE-AD Phase2bstudy of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis (AD). Proof-of-concept efficacy and safety data from a Phase1bstudy of rezpegaldesleukin in atopic dermatitis patients were presented at the 2023 EADV Congress.

Dermatitis 36

Dermatitis Clinic Eczema Therapy 36

The Dermatology Digest

FEBRUARY 18, 2025

Just days after snagging dual approvals for moderate-to-severe atopic dermatitis (AD) and prurigo nodularis (PN) in the European Union, nemolizumab (Nemluvio, Galderma) was also granted Marketing Authorization in the United Kingdom (UK) and Switzerland for AD and PN.

Dermatitis 36

Dermatitis Marketing Hospital Clinic 36

The Dermatology Digest

APRIL 7, 2024

A newly developed therapeutic ladder can help guide dermatologists and patients on the use of nonsteroidal treatment options for atopic dermatitis (AD). The dotted red line in the ladder represents the boundary between safer therapies and systemic treatments with more significant safety risks. The study appears in Dermatitis.

Treatments 77

Treatments Dermatitis Therapy Medical 77

The Dermatology Digest

JANUARY 29, 2024

Food and Drug Administration (FDA) for treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older in December 2023. It is the first drug approved for seborrheic dermatitis with a new mechanism of action in over two decades. in seborrheic dermatitis. in seborrheic dermatitis.

Dermatitis 74

Dermatitis Safety Dermatology Treatments 74

Dermatology Times

OCTOBER 16, 2023

The expanded study data correlates with the safety and efficacy of ruxolitinib cream in patients with atopic dermatitis.

Dermatitis 68

Dermatitis Safety 68

Dermatology Times

MAY 6, 2024

Elizabeth Kiracofe, MD, provides a look at an upcoming DermView program that will explore systemic treatments for atopic dermatitis in the context of reproductive health, for patients during pregnancy, pre-pregnancy, postpartum, and breastfeeding.

Dermatitis 36

Dermatitis Safety Treatments 36

The Dermatology Digest

FEBRUARY 14, 2024

Food and Drug Administration (FDA) has accepted Galderma’s Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis (PN) and for adolescents and adults with moderate to severe atopic dermatitis (AD). Galderma is planning for multiple regulatory submissions in 2024.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

The Dermatology Digest

JANUARY 14, 2024

People with seborrheic dermatitis who don’t use topical steroids are 3.5 Zoryve foam is a once-daily steroid-free topical for use in all skin and hair types that effectively clears and controls seborrheic dermatitis. Food and Drug Administration (FDA) approved topical roflumilast foam (Zoryve, Arcutis) for seborrheic dermatitis.

Dermatitis 72

Dermatitis Office Dermatology Safety 72

Dermatology Times

JUNE 2, 2024

James Song, MD, explains combination treatment efficacy, addresses comorbidities, and provides pearls to improve patient safety.

Dermatitis 52

Dermatitis Therapy Safety Treatments 52

Dermatology Times

JULY 19, 2024

Linda Stein Gold, MD, reviews data presented at SPD and elaborates on study design, methodology, and results.

Safety 45

Safety Dermatitis 45

Dermatology Times

FEBRUARY 24, 2025

Panelists discuss the topical treatment option roflumilast for pediatric atopic dermatitis, exploring its mechanism of action, efficacy, safety, and potential role in managing the condition.

Dermatitis 36

Dermatitis Treatments Safety Management 36

Dermatology Times

MARCH 3, 2025

Panelists discuss the topical treatment option tapinarof for pediatric atopic dermatitis, examining its mechanism of action, efficacy, safety, and potential to improve management of the condition in children.

Dermatitis 36

Dermatitis Treatments Safety Management 36

Dermatology Times

FEBRUARY 24, 2025

Panelists discuss the latest advances in topical treatments for pediatric atopic dermatitis, covering newly available options and those on the horizon with a focus on their mechanisms of action, efficacy, and safety profiles.

Dermatitis 36

Dermatitis Treatments Safety 36

Dermatology Times

AUGUST 25, 2023

Christopher Bunick, MD, PhD, discusses a novel tool to visualize key safety results of Janus kinase inhibitors in treating patients with atopic dermatitis.

Safety 36

Safety Dermatitis Tools 36

Dermatology Times

APRIL 5, 2024

Alexandra Golant, MD, explains why she is confident in the latest safety and efficacy data from ruxolitinib trials to treat pediatric patients with atopic dermatitis.

Safety 36

Safety Dermatitis 36

Dermatology Times

AUGUST 24, 2023

Experts discuss the results of a study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).

Safety 36

Safety Dermatitis Treatments 36

Alison Bladh

JANUARY 1, 2025

Skin Conditions Conditions like eczema, psoriasis, or seborrheic dermatitis can irritate the skin around the brows, leading to hair loss. Microblading: Safety and Efficacy in Eyebrow Enhancement. Over-Plucking Years of over-plucking or waxing can damage hair follicles, making it harder for the hairs to regrow over time.

Treatments 52

Treatments Skincare Routine Hydration Therapy 52